On March 6, 2024 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, reported the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting April 5-10 in San Diego (Press release, BeiGene, MAR 6, 2024, View Source [SID1234640871]). BeiGene has nine abstracts scheduled for poster presentations at AACR (Free AACR Whitepaper).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our presentations at this year’s AACR (Free AACR Whitepaper) showcase our ongoing development of tislelizumab combinations in solid tumors as we assess the clinical potential of multiple novel immuno-oncology candidates and make data-driven decisions for further development," said Lai Wang, Ph.D., Global Head of Research & Development at BeiGene. "More broadly, they reflect our deep commitment to discovering innovative new medicines for cancer patients, including by pioneering novel mechanisms like targeted degradation."
BeiGene will present results from the AdvanTIG-204 Phase 2 study of tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) in first-line limited-stage small cell lung cancer (SCLC) as well as results of a biomarker study of the same doublet in the setting of first-line non-small cell lung cancer (NSCLC). An ongoing, global Phase 3 trial of ociperlimab plus tislelizumab in stage IV, PD-L1 high NSCLC, AdvanTIG-302, will complete enrollment this month (NCT04746924). An additional clinical presentation includes the first data from a Phase 1a dose escalation study of BGB-10188, a phosphatidylinositol 3 kinase delta (PI3Kδ) inhibitor, plus tislelizumab in patients with solid tumors.
BeiGene will also be presenting preclinical characterizations of several novel molecules from its internal discovery engine, including a CEA x 4-1BB bispecific antibody and a chimeric degradation activation compound (CDAC) targeting BTK, BGB-16673. Clinical data from an ongoing Phase 1 study of BGB-16673 in relapsed/refractory B-cell malignancies were presented at ASH (Free ASH Whitepaper) 2023, demonstrating clinical responses and a tolerable safety profile in heavily pre-treated patients with B-cell malignancies, including those with BTK inhibitor-resistant disease (NCT05006716).
An additional preclinical presentation highlights the therapeutic potential of the triple-combination of tislelizumab with anti-LAG-3 (LBL-007) and anti-TIM-3 (surzebiclimab); this combination is being evaluated in an ongoing Phase 2 study in head and neck squamous cell carcinoma (NCT05909904).
BeiGene Presentations During AACR (Free AACR Whitepaper) 2024
Abstract Title
Abstract #
Presentation
Time (PDT)
Lead Author
Preclinical
Characterization of the correlation between BTK
degradation and tumor growth inhibition of the
BTK target protein degraders using PK/PD
modeling
2110
Monday, April 8
9 a.m. – 12:30 p.m.
Section 30
Board #1
Y. Wu
BGB-B167, a first-in-class 4-1BB/CEACAM5
bispecific antibody, exhibits potent in vitro and in
vivo anti-tumor activity and superior safety profile
in preclinical models
2371
Monday, April 8
9 a.m. – 12:30 p.m.
Section 38
Board #17
Z. Li
Translational assessment of triple combination
with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-
3) and surzebiclimab (anti-TIM-3) highlights its
strong anti-tumor activity and clinical potential in
solid tumors such as HNSCC
4041
Tuesday, April 9
9 a.m. – 12:30 p.m.
Section 3
Board #17
H. Zhu
Clinical
Exploration of potential biomarkers correlated
with efficacy of ociperlimab (anti-TIGIT) plus
tislelizumab (anti-PD1) in 1L PD-L1+ non-small
cell lung cancer (NSCLC)
CT053
Monday, April 8
9 a.m. – 12:30 p.m.
Section 48
Board #3
S. Kim
A first in human, phase 1a, dose escalation study
of BGB 10188, a phosphatidylinositol 3 kinase
delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1)
in patients with solid tumors
CT189
Tuesday, April 9
9 a.m. – 12:30 p.m.
Section 48
Board #17
R. Cosman
AdvanTIG-204: A phase 2, multicenter,
randomized, 3-arm, open-label study investigating
the preliminary efficacy and safety of ociperlimab
(anti-TIGIT) + tislelizumab (anti-PD-1) +
concurrent chemoradiotherapy (cCRT) in patients
with untreated limited-stage small cell lung cancer
(SCLC)
CT255
Tuesday, April 9
1:30 p.m. – 5 p.m. Section 48
Board #14
Y. Gong
BGB-A317-LBL-007-202 (NCT06010303): A
phase 2, randomized, active-controlled, open-
label study to evaluate the efficacy and safety of
LBL 007 (anti-LAG-3) in combination with
tislelizumab (TIS; anti-PD-1) plus chemotherapy
(chemo) as first-line (1L) treatment in patients
with unresectable locally advanced/metastatic
esophageal squamous cell carcinoma (ESCC)
CT274
Tuesday, April 9
1:30 p.m. – 5 p.m. Section 50
Board #4
S. Park
Liberty-201 (NCT05609370): Maintenance
fluoropyrimidine and bevacizumab with or without
anti-lymphocyte activation gene-3 (LAG-3)
antibody LBL-007 plus anti-programmed cell
death protein-1 (PD-1) antibody tislelizumab (TIS)
for patients (pts) with metastatic or unresectable
microsatellite stable (MSS)/mismatch repair
proficient (pMMR)colorectal cancer (CRC)
CT276
Tuesday, April 9 1:30 p.m. – 5 p.m.
Section 50
Board #6
H.-J. Lenz
BGB-LC-201 (NCT05635708): A phase 2, open-
label, multi-arm study of tislelizumab (TIS; anti-
PD-1) in combination with investigational agents
+/- chemotherapy as first-line treatment for
patients with locally advanced, unresectable, or
metastatic non-small cell lung cancer (NSCLC)
CT277
Tuesday, April 9
1:30 p.m. – 5 p.m. Section 50
Board #7
G. Blumenschein
About Tislelizumab
Tislelizumab is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD‑1) monoclonal antibody with high affinity and binding specificity against PD‑1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.